Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
This study is currently recruiting participants.
Verified March 2013 by Region Skane
Sponsor:
Region Skane
Information provided by (Responsible Party):
Region Skane
ClinicalTrials.gov Identifier:
NCT01699802
First received: September 25, 2012
Last updated: March 11, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose is to investigate how the adsorptive capacity of the active carbon filter to carbon dioxide in an anaesthetic gas reflector (AnaConDa) is affected by adding inhaled anaesthetic agent.
The hypothesis is that addition of inhaled anaesthetic agent will affect the amount of adsorption of carbon dioxide to the active carbon and thereby affect rebreathing of carbon dioxide.
| Condition | Intervention |
|---|---|
|
Ischemic Heart Disease |
Other: Inhaled anaesthetic agent |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa) |
Resource links provided by NLM:
Further study details as provided by Region Skane:
Primary Outcome Measures:
- Volume of carbon dioxide rebreathing from an anesthetic gas reflector [ Time Frame: 2 hours ] [ Designated as safety issue: No ]Tidal carbon dioxide volume rebreathed from an anesthetic gas reflector correlated to concentration of delivered anesthetic gas.
Secondary Outcome Measures:
- Quantification of ventilatory requirements to maintain isocapnia with the use of an anesthetic gas reflector. [ Time Frame: 2 hours ] [ Designated as safety issue: No ]Changes of tidal volume required to maintain constant alveolar ventilation will be assessed by continuous measurement of exhaled tidal carbon dioxide volume, the latter to be maintained at a constant value.
| Estimated Enrollment: | 12 |
| Study Start Date: | September 2012 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Inhaled anaesthetic agent
The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
|
Other: Inhaled anaesthetic agent |
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- elective coronary artery by-pass graft surgery
- elective valve replacement surgery
- normal left ventricular ejection fraction on preoperative echocardiography
Exclusion Criteria:
- obstructive lung disease
- restrictive lung disease
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01699802
Contacts
| Contact: Gunnar Malmkvist, M.D. Ph.D. | +46 46 171035 | gunnar.malmkvist@skane.se |
Locations
| Sweden | |
| Skane University Hospital Lund, Cardiothoracic Intensive Care | Recruiting |
| Lund, Sweden, SE-221 85 | |
| Contact: Louise C Walther Sturesson, M.D. +46 46 171953 louise.walther_sturesson@med.lu.se | |
Sponsors and Collaborators
Region Skane
Investigators
| Principal Investigator: | Mikael Bodelsson, Professor | Divison of Surgery, Department of Anaesthesia, Skane University Hospital, Lund, Sweden |
More Information
No publications provided
| Responsible Party: | Region Skane |
| ClinicalTrials.gov Identifier: | NCT01699802 History of Changes |
| Other Study ID Numbers: | 2012/148 |
| Study First Received: | September 25, 2012 |
| Last Updated: | March 11, 2013 |
| Health Authority: | Sweden: Medical Products Agency |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Heart Diseases Coronary Disease Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases |
Vascular Diseases Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013